Drug Profile
Research programme: gynaecological disorder therapeutics - BetterLife Pharma
Alternative Names: PVT 001; PVT 004Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Pivot Pharmaceuticals
- Developer BetterLife Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dysmenorrhoea; Hot flashes
Most Recent Events
- 25 Aug 2023 Discontinued - Preclinical for Dysmenorrhoea in USA (unspecified route) (BetterLife Pharma pipeline, August 2023)
- 25 Aug 2023 Discontinued - Preclinical for Hot flashes in USA (unspecified route) (BetterLife Pharma pipeline, August 2023)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Dysmenorrhoea in USA